# Aligos Therapeutics, Inc.: overview ALGS · Nasdaq · CIK 1799448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/algs.md) · [Financials](/companies/algs/financials.md) · [Filings](/companies/algs/filings.md) · [Insiders](/companies/algs/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-336851.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-336851). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,250](/filings/0001193125-25-268203.md) | [606 d](/filings/0001193125-26-092614.md) | [311](/filings/0001193125-26-212001.md) | [965](/filings/0001193125-26-336851.md) | [741](/filings/0001193125-25-268203.md) | [169 d](/filings/0001193125-26-092614.md) | [2,830](/filings/0001193125-26-212001.md) | [0.0](/filings/0001193125-26-336851.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1610.5%)](/filings/0001193125-25-268203.md) | [(3393.2%) d](/filings/0001193125-26-092614.md) | [(6187.5%)](/filings/0001193125-26-212001.md) | [(1924.0%)](/filings/0001193125-26-336851.md) | [(3827.4%)](/filings/0001193125-25-268203.md) | [(12907.7%) d](/filings/0001193125-26-092614.md) | [(951.6%)](/filings/0001193125-26-212001.md) | not reported | | Net margin | % | [(1540.7%)](/filings/0001193125-25-268203.md) | [(13556.1%) d](/filings/0001193125-26-092614.md) | [13854.7%](/filings/0001193125-26-336851.md) | [(1643.8%)](/filings/0001193125-26-336851.md) | [(4256.0%)](/filings/0001193125-25-268203.md) | [(11763.9%) d](/filings/0001193125-26-092614.md) | [(814.1%)](/filings/0001193125-26-336851.md) | not reported | | Diluted EPS | $ per share | [(3.07)](/filings/0001193125-25-268203.md) | not reported | [(2.11)](/filings/0001193125-26-212001.md) | [(1.53)](/filings/0001193125-26-336851.md) | [(3.04)](/filings/0001193125-25-268203.md) | not reported | [(2.21)](/filings/0001193125-26-212001.md) | [(0.14)](/filings/0001193125-26-336851.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-22-003365.md) | [0.0](/filings/0000950170-23-007033.md) | [6.2](/filings/0000950170-25-035929.md) | [3.6](/filings/0001193125-26-092614.md) | [2.2](/filings/0001193125-26-092614.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(1423.5%)](/filings/0000950170-25-035929.md) | [(2469.0%)](/filings/0001193125-26-092614.md) | [(4024.9%)](/filings/0001193125-26-092614.md) | | Net margin | % | not reported | not reported | [(1416.2%)](/filings/0000950170-25-035929.md) | [(3633.6%)](/filings/0001193125-26-092614.md) | [(1106.7%)](/filings/0001193125-26-092614.md) | | Diluted EPS | $ per share | [(3.22)](/filings/0000950170-23-007033.md) | [(2.25)](/filings/0000950170-24-029953.md) | [(34.20)](/filings/0000950170-25-035929.md) | [(20.94)](/filings/0001193125-26-092614.md) | [(2.45)](/filings/0001193125-26-092614.md) | | Free cash flow | $m | [(117)](/filings/0000950170-23-007033.md) | [(80.3)](/filings/0000950170-24-029953.md) | [(79.0)](/filings/0000950170-25-035929.md) | [(80.9)](/filings/0001193125-26-092614.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/algs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $2.6m | 444,110 | | Unchanged | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $2.4m | 412,000 | | Unchanged | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $1.9m | 327,237 | | Unchanged | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.4m | 246,579 | | Reduced −20,556 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $1.0m | 177,362 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.0m | 175,543 | | Reduced −2,719 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $479.2k | 83,055 | | Unchanged | | [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $439.9k | 76,247 | | Unchanged | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $383.5k | 66,463 | | Added +55,485 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $346.1k | 59,986 | | Added +22,925 | ## Recent filings [All 346 filings](/companies/algs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-15 | 16:03 ET | [8-K](/filings/0001193125-26-391880.md) | 1.01 Entry into a material agreement | 0001193125-26-391880 | | 2026-08-06 | 08:07 ET | [10-Q](/filings/0001193125-26-336851.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336851 | | 2026-08-06 | 08:00 ET | [8-K](/filings/0001171843-26-005294.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005294 | | 2026-06-26 | 16:02 ET | [8-K](/filings/0001193125-26-285426.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-285426 | | 2026-06-24 | 16:30 ET | [SCHEDULE 13D](/filings/0001193125-26-281134.md) | Ownership report, active investor | 0001193125-26-281134 | | 2026-05-07 | 16:18 ET | [10-Q](/filings/0001193125-26-212001.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212001 | | 2026-05-07 | 16:08 ET | [8-K](/filings/0001171843-26-003156.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003156 | | 2026-04-29 | 16:25 ET | [DEF 14A](/filings/0001193125-26-191843.md) | Proxy statement, period 2026-06-25 | 0001193125-26-191843 | | 2026-04-21 | 16:32 ET | [8-K](/filings/0001193125-26-166987.md) | 1.01 Entry into a material agreement | 0001193125-26-166987 | | 2026-04-14 | 16:17 ET | [8-K](/filings/0001193125-26-154927.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-154927 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092614.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5eca3cc5-ecd2-45a4-8e95-6de0db40cbf2) ## About the filer - CIK: 1799448 - Tickers: ALGS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.